Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
1.
Braz. j. med. biol. res ; 48(6): 528-536, 06/2015. tab, graf
Article in English | LILACS | ID: lil-748220

ABSTRACT

This study aimed to determine the role of mitochondrial adenosine triphosphate-sensitive potassium (mitoKATP) channels and protein kinase C (PKC)-ε in the delayed protective effects of sevoflurane preconditioning using Langendorff isolated heart perfusion models. Fifty-four isolated perfused rat hearts were randomly divided into 6 groups (n=9). The rats were exposed for 60 min to 2.5% sevoflurane (the second window of protection group, SWOP group) or 33% oxygen inhalation (I/R group) 24 h before coronary occlusion. The control group (CON) and the sevoflurane group (SEVO) group were exposed to 33% oxygen and 2.5% sevoflurane for 60 min, respectively, without coronary occlusion. The mitoKATP channel inhibitor 5-hydroxydecanoate (5-HD) was given 30 min before sevoflurane preconditioning (5-HD+SWOP group). Cardiac function indices, infarct sizes, serum cardiac troponin I (cTnI) concentrations, and the expression levels of phosphorylated PKC-ε (p-PKC-ε) and caspase-8 were measured. Cardiac function was unchanged, p-PKC-ε expression was upregulated, caspase-8 expression was downregulated, cTnI concentrations were decreased, and the infarcts were significantly smaller (P<0.05) in the SWOP group compared with the I/R group. Cardiac function was worse, p-PKC-ε expression was downregulated, caspase-8 expression was upregulated, cTnI concentration was increased and infarcts were larger in the 5-HD+SWOP group (P<0.05) compared with the SWOP group. The results suggest that mitoKATP channels are involved in the myocardial protective effects of sevoflurane in preconditioning against I/R injury, by regulating PKC-ε phosphorylation before ischemia, and by downregulating caspase-8 during reperfusion.


Subject(s)
Animals , Male , Ischemic Preconditioning, Myocardial/methods , Methyl Ethers/pharmacology , Myocardial Reperfusion Injury/prevention & control , Platelet Aggregation Inhibitors/pharmacology , Potassium Channels/pharmacology , Protein Kinase C/pharmacology , Anti-Arrhythmia Agents/pharmacology , Blotting, Western , /analysis , Decanoic Acids/pharmacology , Heart/drug effects , Heart/physiopathology , Hemodynamics/drug effects , Hydroxy Acids/pharmacology , Ischemia/prevention & control , Protective Agents/pharmacology , Random Allocation , Rats, Sprague-Dawley , Reproducibility of Results , Time Factors , Troponin I/analysis
2.
Journal of Korean Medical Science ; : 380-386, 2010.
Article in English | WPRIM | ID: wpr-161042

ABSTRACT

Polyphenol (-)-epigallocatechin gallate (EGCG), the most abundant catechin of green tea, appears to attenuate myocardial ischemia/reperfusion injury. We investigated the involvement of ATP-sensitive potassium (K(ATP)) channels in EGCG-induced cardioprotection. Isolated rat hearts were subjected to 30 min of regional ischemia and 2 hr of reperfusion. EGCG was perfused for 40 min, from 10 min before to the end of index ischemia. A nonselective K(ATP) channel blocker glibenclamide (GLI) and a selective mitochondrial K(ATP) (mK(ATP)) channel blocker 5-hydroxydecanoate (HD) were perfused in EGCG-treated hearts. There were no differences in coronary flow and cardiodynamics including heart rate, left ventricular developed pressure, rate-pressure product, +dP/dt(max), and -dP/dt(min) throughout the experiments among groups. EGCG-treatment significantly reduced myocardial infarction (14.5+/-2.5% in EGCG 1 micrometer and 4.0+/-1.7% in EGCG 10 micrometer, P<0.001 vs. control 27.2+/-1.4%). This anti-infarct effect was totally abrogated by 10 micrometer GLI (24.6+/-1.5%, P<0.001 vs. EGCG). Similarly, 100 micrometer HD also aborted the anti-infarct effect of EGCG (24.1+/-1.2%, P<0.001 vs. EGCG ). These data support a role for the K(ATP) channels in EGCG-induced cardioprotection. The mK(ATP) channels play a crucial role in the cardioprotection by EGCG.


Subject(s)
Animals , Humans , Male , Rats , Anti-Arrhythmia Agents/pharmacology , Antioxidants/pharmacology , Catechin/analogs & derivatives , Decanoic Acids/pharmacology , Glyburide/pharmacology , Heart/drug effects , Hemodynamics , Hydroxy Acids/pharmacology , KATP Channels/metabolism , Mitochondria, Heart/drug effects , Myocardial Infarction/pathology , Myocardial Ischemia/pathology , Potassium Channel Blockers/pharmacology , Rats, Wistar
SELECTION OF CITATIONS
SEARCH DETAIL